Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Shares Shorted: Short Interest Up 185.6% in October

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 288,479 shares, a growth of 185.6% from the October 15th total of 101,010 shares. Based on an average trading volume of 1 shares, the short-interest ratio is presently 288,479.0 days.

Neuren Pharmaceuticals Stock Performance

OTCMKTS NURPF remained flat at C$13.76 during mid-day trading on Friday. The business has a 50 day simple moving average of C$14.51 and a two-hundred day simple moving average of C$11.66. Neuren Pharmaceuticals has a fifty-two week low of C$7.70 and a fifty-two week high of C$17.25.

Neuren Pharmaceuticals Company Profile

(Get Free Report)

Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on developing treatments for serious neurodevelopmental disorders. Based in Melbourne, the company’s research centers on therapies intended to address conditions with limited treatment options. Its lead partnered medicine, trofinetide, is marketed in the United States by Acadia Pharmaceuticals as DAYBUE for Rett syndrome. Neuren developed the drug and licensed commercialization rights to Acadia. Neuren is also developing NNZ-2591, an investigational treatment being studied for several neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome, Angelman syndrome and Prader-Willi syndrome.

Featured Stories

Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.